Weighing Risks and Benefits of Liraglutide — The FDA's Review of a New Antidiabetic Therapy

Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.

From the Division of Metabolism and Endocrinology Products (M.P.) and the Office of Drug Evaluation II (C.R.), Office of New Drugs, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD.

This article (10.1056/NEJMp1001578) was published on February 17, 2010, at NEJM.org.